Processing your request


please wait...

 | Case Page

 | Case Page |

Case Page

 

Allergan plc

Case Summary

Allergan plc Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 09/20/2019 (Ongoing date of last review)

Filing Date: December 21, 2018

Plaintiff's law firm issued a press release on December 21, 2018, announcing the filing of the lawsuit. According to the press release, the Complaint alleges that, during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. Specifically, the Complaint alleges that throughout the Class Period Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.

On March 21, 2019, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. Lead Plaintiff filed a consolidated amended Complaint on April 19. Defendants filed a Motion to Dismiss the consolidated amended Complaint on May 24. On September 20, the Court issued an Order granting in part and denying in part the Motion to Dismiss.

Company & Securities Information

Defendant: Allergan plc

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: Ireland

SECURITIES INFORMATION:

Ticker Symbol: AGN
Company Market: New York SE
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Thomas F. Cook, et al. v. Allergan plc, et al.

COURT: S.D. New York
DOCKET #: 18-CV-12089
JUDGE: Hon. Colleen McMahon
DATE FILED: 12/21/2018
CLASS PERIOD START: 05/09/2017
CLASS PERIOD END: 12/19/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Block & Leviton LLP
  2. Finkelstein, Blankinship, Frei-Pearson & Garber, LLP
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Complaint for Violations of the Federal Securities Laws 12/21/2018
2 Decision and Order Appointing Lead Plaintiff, Consolidating Cases, and Setting Schedule 03/21/2019
3 U.S. District Court Civil Docket 03/22/2019

Reference Complaint

In re Allergan PLC Securities Litigation

COURT: S.D. New York
DOCKET #: 18-CV-12089
JUDGE: Hon. Colleen McMahon
DATE FILED: 04/19/2019
CLASS PERIOD START: 01/30/2017
CLASS PERIOD END: 12/19/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Pomerantz LLP (New York)
    600 Third Avenue, 20th Floor, Pomerantz LLP (New York), NY 10016
    212.661.1100 212.661.8665 · info@pomerantzlaw.com/
  2. Thornton Law Firm, LLP
    100 Summer Street, 30th Floor, Thornton Law Firm, LLP, MA 02110
    617.531.3933 ·
Reference Complaint (REF) Filings:
No Document Title Filing Date
1 Consolidated Amended Class Action Complaint 04/19/2019
2 U.S. District Court Civil Docket 09/20/2019
3 Decision and Order Granting in Part and Denying in Part Defendants' Motion to Dismiss 09/20/2019

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases